Sarah Polowin

Lead discussions on infrastructure for camp and accessible buildings Canada wide. Communicate the priorities of members and provincial interests at the federal level Canada wide with respect to the 2026 budget and beyond. Advance discussions on funding for digitization of Easter Seals programs and services; leading meetings advocating for new funding and new funding models for charities. Coordinate meetings with the Canadian Ambassador to America and relevant officials to discuss matters of Canada -US interest related to disability and inclusion and organize events in partnership with the embassy on transport, employment, education and inclusion. Lead meetings, arrange discussions and coordinate events related to budget 2026 as it relates to all advocacy initatives of Easter Seals Canada and all programs, grants, funding and services impacting persons with disabilities. Lead discussions and arrange meetings relating to the ongoing development of the Canada Disability Benefit. Champion Buy Canada policy as it relates to all persons with disabilities and all aspects of procurement. Discuss and lead meetings related to any emerging artificial intelligence legislation; scope of these meetings may include safeguards for persons with disabilities and the impact of AI on employment and persons with disabilities. Coordinate and lead discussions related to funding for Easter Seals Canada in budget 2025 and beyond. Support meetings and policy collaboration related to Canada's work on the global level for all persons with disabilities, via the United Nations, between relevant stakeholders. Arrange discussions and meetings for relevant provincial members and/or introduce ESC officials to Government of Canada officials to discuss policy and funding change's to Jordan's Principle. Discuss federal - provincial issues related to potential clawbacks of the Canada Disability Benefit at the provincial level. Discuss the potential of funding from Elections Canada to support communications projects related to accessibility voting. Advocate for accessible policies, programs and related initiatives as it relates to the build of the new high-speed rail line between Toronto and Montreal, as it relates to all persons with disabilities. Lead meetings and discussions related to potential education funding during a future election campaign. Discuss potential tariffs as they may relate to medical equipment and mobility devices. Discuss the care economy as it relates to seniors with disabilities. Lead discussions on the implementation of national dental and pharmacare programs as they relate to persons with disabilities. Encourage increased procurement by the Government of Canada by enhanced buying from businesses and entities owned by persons with disabilities; lead meetings related to procurement policy in Canada and a more committed effort to procure products, services, land and/or entities that support the principles of a barrier-free Canada. Lead discussions and meetings related to accessible sport in Canada. To discuss Easter Seals camps programming and impact as well as the organization's broad national role in advocacy and federal mandate with Members of the House of Commons and Senate To discuss autism awareness as it relates to Autism Awareness Month and related policies and legislation. Lead discussions and meetings related to the supply chain, constraints and how it impacts Canadians living with a disability. Lead advocacy efforts on conversations related to the regulation phase and implementation of the Canada Disability Benefit (Bill C-22) Act Discuss the impact of climate change on persons with disabilities, long term infrastructure planning and development Discuss public safety related to person with disabilities living in Canada particularly as it relates to cities, transport and housing. Discuss private members statement, M-78/Inclusion of people with disabilities; coordinate relevant meetings and offer Easter Seals support. Discuss polici

Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i). Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada. Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases. Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.

Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease. Implementation of Canada's action plan for pain and federal initiatives related to pain management. Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework. Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Assist CanFASD in advocating for the development of a National FASD Strategy. Advocate for the passage of Bill S-253, National Framework on Fetal Alcohol Spectrum Disorder Act

Securing funding to expand CMHA programs, funding for mental health and mental health research Development of national standards for access to mental health services. Arranging meetings and outreach with public office holders to discuss mental health and addictions policy, service delivery, and programs.

Seeking the establishment of a federal Canada Water Agency Seeking legislation for a public, universal pharmacare program Seeking just transition legislation that protects workers, communities, and the planet. Seeking a national citizens' assembly on electoral reform so each vote has equal value and there is increased government accountability to all citizens Advocating for all remaining drinking water advisories in First Nations communities to be addressed and lifted

Regulation of pesticides under the Pest Management Regulatory Agency Canada's program regarding research for wheat, corn and soybeans under Agriculture Canada's A-base funded Research Projects. Canada's policy with respect to the rules governing the design and funding of Agristability and Agrirecovery programs that are part of Canada's Business Risk Management Programs for Agriculture. Canada's policy regarding the carbon pricing system treatment of fuels used for drying grain Canada's policy on Free Trade Agreements to ensure that any proposed Agreements improve foreign market access for wheat, corn and soybeans

Ensure the smooth transition of the machinery of government change from DFO to GAC

Federal role in the health system as it relates to funding, the use of federal spending power, and pan-Canadian priorities, including in the areas of physical and digital infrastructure, health workforce, immigration, aging, older adult care, child and youth health, mental health and substance use, palliative care, cybersecurity, Indigenous health, environment, and data. Advancing Canada’s health research and innovation agenda as it relates to funding, policy and program design, and regulatory matters, including in the areas of clinical trials and development of innovative medical treatments.

World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility" World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG) The government's Science and Technology strategy as it relates to the biopharmaceutical industry Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations Smart Regulations as it relates to the biopharmaceutical industry Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits Proposed pharmacare legislation related to any future national pharmacare program Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products New Substances Notification Regulations as it relates to the biopharmaceutical industry Income Tax Act as it relates to biopharmaceutical products Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19 Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Free trade treaty agreement as they relate to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH) Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products Canada's Access to Medicines Regime with respect to ensuring that the program allows for the deli

Infrastructure - Expand opportunities for long-term investors to support infrastructure investment, including opportunities to support investment in housing. Pensions & savings plans – Engage with public office holders regarding enhancing retirement and savings security for Canadians through retirement planning, public and registered savings plans, annuities, etc. Prescription drugs - Seeking to raise awareness about prescription drug & workplace benefit coverage. Group benefits & paramedical health care – Engage with public office holders regarding health care programs and policy that may impact group benefit plans. Climate/Environment – Engagements related to the impacts of extreme weather on the health and wellness of Canadians and expanding opportunities to meet our decarbonization commitments. International relations & trade – Engage with public office holders regarding international relations as it relates to Canada’s insurance industry. This includes how best to maximize the benefits of Canada’s trade relations for the industry and broader economy. Insurance and health regulation and legislation - Engage with public office holders regarding Canada’s financial services and health care sectors, in relation to the insurance industry. This may include the industry’s governing legislation and regulations, taxation policy, administration, and related issues, guidelines & rules. Cyber security, data, and privacy – Engage with public office holders on how to ensure the safety and integrity of Canada’s insurance industry’s data and technology systems. This may include engagement on privacy legislation, policy, and technological innovation in the insurance industry.